Refocus Group
Refocus Group is a privately held U.S. medical-device company developing the investigational VisAbility Micro Insert System, a binocular scleral implant designed to restore near vision in presbyopia patients while preserving distance vision, currently in clinical trials pending FDA approval.
- Company typePrivate
- Founded1994
- HeadquartersDallas, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Refocus Group does
Refocus Group, Inc. is a privately held U.S. medical-device company that has spent more than two decades developing the VisAbility Micro Insert System, an implantable binocular device designed to restore near vision in patients with presbyopia without compromising distance vision. The company describes the product as the world's first binocular presbyopic treatment that works outside the visual axis — a positioning that differentiates it from corneal inlays (e.g., AcuFocus's KAMRA, where current CEO Mike Judy previously worked) and intraocular lens-based approaches. The device remains investigational and limited by U.S. law to investigational use, with Refocus Group operating in a clinical-trial posture pending FDA approval and providing no disclosed revenue, pricing, or commercial launch date.
Refocus Group firmographics
Firmographics- Name
- Refocus Group
- Legal name
- Refocus Group, Inc.
- Website
- https://refocus-group.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Refocus Group is a privately held U.S. medical-device company developing the investigational VisAbility Micro Insert System, a binocular scleral implant designed to restore near vision in presbyopia patients while preserving distance vision, currently in clinical trials pending FDA approval.
- Ownership category
- akta.pro rank
Refocus Group industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)
Keywords
Where Refocus Group is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Refocus Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Revenue will be generated from the sale of the VisAbility Micro Insert System to eye care professionals. The device is an investigational medical device currently in clinical trials, pending FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Refocus Group product offering
Product offeringCore offering
Refocus Group develops the VisAbility™ Micro Insert System, an investigational implantable ophthalmic device designed to restore near vision in both eyes for patients with presbyopia without affecting distance vision. The system works outside the visual axis and is intended to be implanted by trained ophthalmologists and optometrists as a binocular treatment that reduces or eliminates dependence on reading glasses. The device is currently limited by U.S. law to investigational use, with Refocus Group conducting clinical trials to support future regulatory approval and commercial launch.
Product overview
Refocus Group offers a single unified product—the VisAbility™ Micro Insert System. This is an investigational medical device designed for the treatment of presbyopia, intended to restore near vision in both eyes while maintaining distance vision. The system represents the world's first binocular presbyopic treatment approach that works outside the visual axis, enabling patients to reduce or eliminate their dependence on reading glasses.
Differentiator
Problem solved
Functional benefit
Brands
- VisAbility: VisAbility™ Micro Insert System is an investigational medical device for near vision correction in patients with presbyopia. It is the world's first binocular presbyopic treatment that works outside the visual axis.
Products and services
- VisAbility™ Micro Insert System Investigational binocular ophthalmic implant designed to restore near vision in patients with presbyopia without affecting distance vision; works outside the visual axis and is intended to reduce or eliminate dependence on reading glasses. Implanted by trained ophthalmologists and optometrists in the eye care professional setting.
Quantifiable outcome
- Patients who participated in clinical trials showed improved near vision in both eyes and reduced need for reading glasses
Companies that use Refocus Group
Customer profileSegments2 records
Ideal customer profiles2 records
Refocus Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Refocus Group partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Refocus Group competitors and assessment
Company assessmentBroad incumbents
- Alcon: Global ophthalmic medical device leader offering multifocal and presbyopia-correcting IOLs (e.g., PanOptix) along with refractive surgery platforms. Overlaps with Refocus in the presbyopia treatment market but operates at vastly greater scale across the full ophthalmic portfolio.
- Carl Zeiss Meditec: Manufactures refractive surgery systems (SMILE, excimer lasers) and ophthalmic IOLs, including presbyopia-correcting lenses. Comparable as a refractive/presbyopia device incumbent with global distribution into ophthalmic surgical centers.
- Johnson & Johnson Vision: J&J Vision competes in presbyopia through the TECNIS Symfony extended depth-of-focus IOL and other refractive surgical platforms. As a broad incumbent with a deep cataract/refractive sales force, it represents both an overlapping product offering and a competitive commercialization benchmark.
- Bausch + Lomb: Major ophthalmic device and vision care company whose surgical franchise includes accommodating IOLs such as Crystalens for presbyopia. CEO Mike Judy previously led global surgical marketing at Bausch + Lomb, and the company competes in the same presbyopia correction category as VisAbility.
Emerging players
- Orasis Pharmaceuticals: Develops a corrective eye drop therapy (CSF-1 / pilocarpine-based) for presbyopia. Targets the same patient population seeking to reduce dependence on reading glasses, representing a non-invasive competitive alternative to Refocus's surgical implant.
- STAAR Surgical: Makes the Visian Implantable Collamer Lens (ICL), a refractive implant placed in the eye for vision correction. Comparable to Refocus as an implantable refractive device company, though addressing myopia rather than presbyopia, and at a different commercial stage.
- Glaukos Corporation: Pioneered minimally-invasive scleral/suprachoroidal implant-based approaches in ophthalmology (initially for glaucoma, now expanding). Comparable to Refocus for its expertise in implant-based ophthalmic platforms that work outside the visual axis, even though the therapeutic indication differs.
- Visus Therapeutics: Clinical-stage company developing pharmacologic presbyopia correction treatments (e.g., brimonidine-based formulations). Competes for presbyopia share via eye drops, intersecting with Refocus on patient indication while pursuing a different delivery modality.
- Lenz Therapeutics: Late-stage clinical company developing pharmacologic eye drops for presbyopia (e.g., aceclidine-based therapies). Competes for the same presbyopia treatment opportunity as Refocus via a non-surgical mechanism, making it a category competitor rather than a direct device peer.
Direct peers
- AcuFocus: AcuFocus developed the KAMRA corneal inlay, the closest direct competitor — a small-aperture implant for presbyopia. Refocus CEO Mike Judy was AcuFocus's Chief Commercial Officer, making this the single most directly comparable company in terms of product category, mechanism (implantable presbyopia device), and commercial model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Refocus Group social profiles
Digital presenceRefocus Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Refocus Group leadership team
Management profileNumber of profiles
Profiles9 records
Refocus Group funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Refocus Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Refocus Group
What does Refocus Group do?
Refocus Group develops the VisAbility™ Micro Insert System, an investigational implantable ophthalmic device designed to restore near vision in both eyes for patients with presbyopia without affecting distance vision. The system works outside the visual axis and is intended to be implanted by trained ophthalmologists and optometrists as a binocular treatment that reduces or eliminates dependence on reading glasses. The device is currently limited by U.S. law to investigational use, with Refocus Group conducting clinical trials to support future regulatory approval and commercial launch.
Is Refocus Group a public or private company?
Refocus Group is a private company. It is classified as venture growth investor backed and is currently operating.
When was Refocus Group founded?
Refocus Group was founded in 1994. It employs 11 to 50 people.
Where is Refocus Group based?
Refocus Group is headquartered in Dallas, United States, in the North America region.
How does Refocus Group make money?
One revenue line is on record: medical Device Sales.
Who are Refocus Group's main competitors?
Broad incumbents on record are Alcon, Carl Zeiss Meditec, Johnson & Johnson Vision and Bausch + Lomb. Emerging players are Orasis Pharmaceuticals, STAAR Surgical, Glaukos Corporation, Visus Therapeutics and Lenz Therapeutics. AcuFocus is listed as a direct peer.
Does Refocus Group have an API?
No public API is recorded for Refocus Group.
What industry is Refocus Group in?
Refocus Group's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAG, Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance). Its NAICS code is 339115 and its SIC code is 3851.